Cell-based therapies for Huntington's disease

Drug Discovery Today

Volumn 19, Issue 7, 2014, Pages 980-984

  Chen, Yiju ^a,b   Carter, Richard L ^a,b   Cho, In K ^a,b   Chan, Anthony W S ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; HTT PROTEIN, HUMAN; NERVE PROTEIN;

CELL DIFFERENTIATION; CELL MIGRATION; CELL THERAPY; CELL TYPE; EMBRYONIC STEM CELL; FETAL CELL THERAPY; GENE REPRESSION; GENE THERAPY; HOST CELL; HUNTINGTON CHOREA; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; RODENT MODEL; SAFETY; STEM CELL TRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL THERAPY; GENETICS; HUMAN; HUNTINGTON DISEASE; INDUCED PLURIPOTENT STEM CELL; PROCEDURES; TRANSPLANTATION;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; GENETIC THERAPY; HUMANS; HUNTINGTON DISEASE; INDUCED PLURIPOTENT STEM CELLS; NERVE TISSUE PROTEINS;

EID: 84903763248     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.02.012     Document Type: Review

References (55)

1. M. DiFiglia et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993
2. J.F. Gusella, and M.E. MacDonald Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease Nat. Rev. Neurosci. 1 2000 109 115
3. A. Reiner et al. Differential loss of striatal projection neurons in Huntington disease Proc. Natl. Acad. Sci. U. S. A. 85 1988 5733 5737
4. J.B. Carroll et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin Mol. Ther. 19 2011 2178 2185
5. J.X. Hu et al. Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway Nucleic Acids Res. 40 2012 11270 11280
6. M. Matsui, and D.R. Corey Allele-selective inhibition of trinucleotide repeat genes Drug Discov. Today 17 2012 443 450
7. J.L. McBride et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi Proc. Natl. Acad. Sci. U. S. A. 105 2008 5868 5873 (Pubitemid 351758464)
8. M. DiFiglia et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits Proc. Natl. Acad. Sci. U. S. A. 104 2007 17204 17209
9. S.Q. Harper et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model Proc. Natl. Acad. Sci. U. S. A. 102 2005 5820 5825 (Pubitemid 40559643)
10. V. Drouet et al. Sustained effects of nonallele-specific Huntingtin silencing Ann. Neurol. 65 2009 276 285
11. X.H. Lu, and X.W. Yang 'Huntingtin holiday': progress toward an antisense therapy for Huntington's disease Neuron 74 2012 964 966
12. D.W. Sah, and N. Aronin Oligonucleotide therapeutic approaches for Huntington disease J. Clin. Invest. 121 2011 500 507
13. I. Dragatsis et al. Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues Development 125 1998 1529 1539
14. E. Cattaneo et al. Normal huntingtin function: an alternative approach to Huntington's disease Nat. Rev. Neurosci. 6 2005 919 930 (Pubitemid 41753086)
15. C.F. Bennett, and E.E. Swayse RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform Annu. Rev. Pharmacol. Toxicol. 50 2010 259 293
16. E.L. Pfister et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients Curr. Biol. 19 2009 774 778
17. H.B. Kordasiewicz et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis Neuron 74 2012 1031 1044
18. D.K. Stiles et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA Exp. Neurol. 233 2012 463 471
19. Y. Zhang, and R.M. Friedlander Using non-coding small RNAs to develop therapies for Huntington's disease Gene Ther. 18 2011 1139 1149
20. H. Peluffo et al. Efficient gene expression from integration-deficient lentiviral vectors in the spinal cord Gene Ther. 20 2013 645 657
21. J. Matrai et al. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk Hepatology 53 2011 1696 1707
22. M.R. Haddad et al. Fetal brain-directed AAV gene therapy results in rapid, robust, and persistent transduction of mouse choroid plexus epithelia Mo. Ther. Nucleic Acids 2 2013 e101
23. A.L. Kendall et al. Functional integration of striatal allografts in a primate model of Huntington's disease Nat. Med. 4 1998 727 729 (Pubitemid 28274676)
24. A.W. Deckel et al. Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants Eur. J. Pharmacol. 93 1983 287 288 (Pubitemid 13009705)
25. A. Klein et al. Brain repair in a unilateral rat model of Huntington's disease: new insights into impairments and restoration of forelimb movement patterns Cell Transplant. 22 2012 1735 1751
26. A.C. Bachoud-Levi et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study Lancet Neurol. 5 2006 303 309
27. R.A. Barker et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease J. Neurol. Neurosurg. Psychiatry 84 2013 657 665
28. G. Cisbani et al. Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability Brain 136 2013 433 443
29. G. Cisbani et al. Single cell suspension methodology favours survival and vascularization of fetal striatal grafts in the YAC128 mouse model of Huntington's disease Cell Transplant. 2013 10.3727/096368913X668636
30. S.T. Lee et al. Slowed progression in models of Huntington disease by adipose stem cell transplantation Ann. Neurol. 66 2009 671 681
31. L. Ma et al. Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice Cell Stem Cell 10 2012 455 464
32. A.D. Carri et al. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-321 medium-sized spiny neurons Development 140 2013 301 312
33. G. El-Akabawy et al. Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease BMC Neurosci. 13 2012 97
34. C.D. Keene et al. A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions Acta Neuropathol. 117 2009 329 338
35. L. Aubry et al. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats Proc. Natl Acad. Sci. U. S. A. 105 2008 16707 16712
36. N.S. Roy et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes Nat. Med. 12 2006 1259 1268 (Pubitemid 44706928)
37. M.N. McCracken et al. Long-term in vivo monitoring of mouse and human hematopoietic stem cell engraftment with a human positron emission tomography reporter gene Proc. Natl. Acad. Sci. U. S. A. 110 2013 1857 1862
38. W.B. Hyslop, and R.C. Semelka Future directions in body magnetic resonance imaging Top. Magn. Reson. Imaging 16 2005 3 14 (Pubitemid 43186775)
39. M.F. Kircher et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors Cancer Res. 63 2003 6838 6846 (Pubitemid 37322966)
40. M. Lewin et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells Nat. Biotechnol. 18 2000 410 414 (Pubitemid 30217528)
41. R. Weissleder Target-specific superparamagnetic MR contrast agents Magn. Reson. Med 22 1991 209 212 discussion 213-205
42. L.G. Remsen et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis Am. J. Neuroradiol. 17 1996 411 418 (Pubitemid 26101942)
43. A. Moore et al. Measuring transferrin receptor gene expression by NMR imaging Biochim. Biophys. Acta 1402 1998 239 249 (Pubitemid 28206918)
44. J.W. Bulte et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination Proc. Natl. Acad. Sci. U. S. A. 96 1999 15256 15261 (Pubitemid 30019799)
45. D. Artemov et al. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles Magn. Reson. Med. 49 2003 403 408 (Pubitemid 36262806)
46. J.W. Bulte et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells Nat. Biotechnol. 19 2001 1141 1147 (Pubitemid 33115700)
47. O. Zurkiya et al. MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter Magn. Reson. Med. 59 2008 1225 1231 (Pubitemid 351813249)
48. G. Vande Velde et al. Evaluation of the specificity and sensitivity of ferritin as an MRI reporter gene in the mouse brain using lentiviral and adeno-associated viral vectors Gene Ther. 18 2011 594 605
49. G. Vande Velde et al. Quantitative evaluation of MRI-based tracking of ferritin-labeled endogenous neural stem cell progeny in rodent brain Neuroimage 62 2012 367 380
50. D. Kaur et al. Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration Brain Res. 1140 2007 188 194 (Pubitemid 46356293)
51. D. Kaur et al. Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease Brain Res. 1297 2009 17 22
52. C. Nakamura et al. Iron-regulated expression and membrane localization of the maga protein in Magnetospirillum sp, strain Amb-1 J. Biochem. 118 1995 23 27
53. B.B. Bartelle et al. Divalent metal transporter, DMT1: a novel MRI reporter protein Magn. Reson. Med. 70 2012 842 850
54. S.H. Yang et al. Towards a transgenic model of Huntington's disease in a non-human primate Nature 453 2008 921 924
55. C.E. Wang et al. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease Hum. Mol. Genet. 17 2008 2738 2751